viralic
Forumer storico
....Ma stai pure a perdere il tuo tempo per rispondere???....non hai capito che è il solito troll che da FOL si è trasferito qui ???
NicOx : Garufi ... e la Rivoluzione Pharma (49 lettori)
- Creatore Discussione Yesod
- Data di Inizio
- Stato
....Ma stai pure a perdere il tuo tempo per rispondere???....non hai capito che è il solito troll che da FOL si è trasferito qui ???
Netzach
Forumer storico
Pfizer Inc. (NYSE
FE) is the largest pharmaceutical company in the world. It owns the cholesterol-lowering drug Lipitor, which brings in a quarter of its revenue and is the best selling medicine in the world as of 2008.[1] However, Pfizer's 2007 sales have stagnated at $48 billion, representing a 0.1% growth from the previous year.[2] Sales of depression drug Zoloft have declined precipitously after its patent expired in 2005. The patent for Lipitor will expire in 2010, and there are no guarantees that another equally profitable drug will come to maturity before then. The cholesterol drug Torcetrapib was once hailed as Pfizer's next blockbuster drug but failed late stage clinical trials in 2006, severely setting back profit expectations and shaking investor confidence.
As the largest player in the market, Pfizer has greater power in marketing and forming alliances.[3] The company also consistently posts the highest dividends in the industry.[3] However, Pfizer faces challenges common to all players in the pharmaceutical industry, including issues surrounding patent expiration and FDA regulation. Pfizer's developmental pipeline included 213 products at the end of 2007,[4] and investors in Pfizer will be betting that one of these drugs is the firm's next big hit.
Pfizer has announced that it plans to shift its research and development focus away from heart disease drugs to cancer and biotechnology drugs, which it says are more profitable. The former category includes the company's most profitable product, Lipitor. [5]
On January 25, 2008, Pfizer agreed to acquire rival Wyeth for $68 billion, or $50.19 per share, a 29 percent premium over the market price before rumors of the deal leaked. After the merger, Pfizer expects annual sales of over $70 billion and net income of over $20 billion. The company has stated that it plans to save $4 billion a year with the merger, which is one of the largest deals to hit Wall Street after the credit crisis.[6]
http://www.wikinvest.com/stock/Pfizer_(PFE)
Chissà se loro hanno già in mente NCX6560 ...
FE) is the largest pharmaceutical company in the world. It owns the cholesterol-lowering drug Lipitor, which brings in a quarter of its revenue and is the best selling medicine in the world as of 2008.[1] However, Pfizer's 2007 sales have stagnated at $48 billion, representing a 0.1% growth from the previous year.[2] Sales of depression drug Zoloft have declined precipitously after its patent expired in 2005. The patent for Lipitor will expire in 2010, and there are no guarantees that another equally profitable drug will come to maturity before then. The cholesterol drug Torcetrapib was once hailed as Pfizer's next blockbuster drug but failed late stage clinical trials in 2006, severely setting back profit expectations and shaking investor confidence. As the largest player in the market, Pfizer has greater power in marketing and forming alliances.[3] The company also consistently posts the highest dividends in the industry.[3] However, Pfizer faces challenges common to all players in the pharmaceutical industry, including issues surrounding patent expiration and FDA regulation. Pfizer's developmental pipeline included 213 products at the end of 2007,[4] and investors in Pfizer will be betting that one of these drugs is the firm's next big hit.
Pfizer has announced that it plans to shift its research and development focus away from heart disease drugs to cancer and biotechnology drugs, which it says are more profitable. The former category includes the company's most profitable product, Lipitor. [5]
On January 25, 2008, Pfizer agreed to acquire rival Wyeth for $68 billion, or $50.19 per share, a 29 percent premium over the market price before rumors of the deal leaked. After the merger, Pfizer expects annual sales of over $70 billion and net income of over $20 billion. The company has stated that it plans to save $4 billion a year with the merger, which is one of the largest deals to hit Wall Street after the credit crisis.[6]
http://www.wikinvest.com/stock/Pfizer_(PFE)
Chissà se loro hanno già in mente NCX6560 ...
Netzach
Forumer storico
Netzach
Forumer storico
Qualcuno teme sempre più la concorrenza ...
http://www.clinicaltrials.gov/ct2/show/NCT00346216?term=pfizer+naproxen+ibuprofen&rank=1
http://www.clinicaltrials.gov/ct2/show/NCT00346216?term=pfizer+naproxen+ibuprofen&rank=1
Aeiou
▲ + 444%
magolibero
..se la sà gira..
beh.. per temere ..temono
anche se lo studio é partito ad Ott06
e dovrebbe terminare Feb13 (..quando si spera il naprox da mò abbia già macinato fatturato)
gigiov
Nuovo forumer
MILANO — «Mi fanno quasi tenerezza, per non dire altro, quelli che nel centrosinistra si sono innamorati di Murdoch. Pensi: un signore che ha scalato e conquistato il Wall Street Journal, bibbia dei repubblicani americani e del capitalismo globale, che ha lanciato Fox-tv, il network che ha sostenuto per due mandati George W. Bush... ». Sorride Pier Silvio Berlusconi raccontando l'apparente paradosso italiano. Apparente soprattutto alla luce dello psicodramma che stanno attraversando i democratici dopo le elezioni sarde. Forse a renderlo così tranquillo è anche il fatto di aver superato il caso Mentana in scioltezza con il colpo di aver preso Alessio Vinci dalla Cnn, incassando anche i complimenti del network tv roccaforte del giornalismo mondiale.
Netzach
Forumer storico
Il caso Mentana mi è parso proprio un colpo basso ...
No comment ...
E meno male che qualcuno diceva che a Mediaset si rispettavano le diversità di opinione.
Mi pare che più che yes-man qualcuno non voglia ...
- Stato